Commentary & Perspectives

Access to Advanced Therapies Hinges on AI and Collaboration

AI and collaboration can transform cell and gene therapy by integrating data, improving manufacturing handoffs, and enabling personalized, scalable treatments.

Share

Access to cell and gene therapies (CGTs) is hindered by the limitations of traditional pharmaceutical models. Addressing these challenges requires innovative strategies, particularly the integration of automation and AI to enhance production efficiency and precision. AI plays a pivotal role in personalizing therapies, optimizing treatment processes, and fostering collaboration among various stakeholders in the CGT supply chain. Blood centers are crucial for leveraging existing patient data and facilitating data-sharing collaborations to enable personalized treatment solutions.

Related Content

Tracing Long-Term Radon Gas Exposure With… Toenails?

The surprising biological archive of past radon gas exposure that may help improve lung cancer screening

Reprogramming the Immune System: Cancer Vaccines, Collaboration, and Communication

From the University of Houston to MD Anderson Cancer Center, Cole Woody’s journey shows how curiosity and collaboration can drive major discoveries. He reflects on the promise of repurposed mRNA vaccines, the technical art of immunology, and the social side of science.

  • November 25, 2025

  • 8 min
Bringing New Ideas to AAV Gene Therapy

As safety concerns and commercial doubts threaten the AAV gene therapy field, new technologies may offer a “well-rounded” solution.